



Aadi Bioscience to Report Second Quarter 2023 Results and Operational Update

August 2, 2023

Company to Host Conference Call and Webcast on Wednesday, August 9, 2023

LOS ANGELES, Aug. 2, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced that it will host a conference call and live webcast on Wednesday, August 9, 2023 at 8:30 am ET (5:30 am PT) to report second quarter 2023 financial results and provide an operational update.

Conference Call Information

Participants may access a live webcast of the call on the "Investors & News" page of the Aadi Bioscience website at www.aadibio.com. To participate via telephone, please register in advance here: [Conference Registration \(vevent.com\)](http://www.aadibio.com/conference-registration). Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of the conference call and webcast will be archived on the website for at least 30 days.

About Aadi Bioscience, Inc.

Aadi is a commercial-stage biopharmaceutical company focused on precision therapies for genetically defined cancers to bring transformational therapies to cancer patients with mTOR pathway driver alterations. Aadi received FDA approval in November 2021, and in February 2022 commenced commercialization of FYARRO[®] for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa).

Aadi is conducting the PRECISION 1 trial, a Phase 2 tumor-agnostic registration-directed study in patients with mTOR inhibitor-naïve malignant solid tumors harboring *TSC1* or *TSC2* inactivating alterations. More information on Aadi's development pipeline is available on the Aadi website at www.aadibio.com and connect with us on [Twitter](https://twitter.com/aadibio) and [LinkedIn](https://www.linkedin.com/company/aadibio).

Contact:

Marcy Graham
IR@aadibio.com



 View original content to download multimedia: <https://www.prnewswire.com/news-releases/aadi-bioscience-to-report-second-quarter-2023-results-and-operational-update-301891484.html>

SOURCE Aadi Bioscience